Welcome to our dedicated page for Turn Therapeutics SEC filings (Ticker: TTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. While no specific filings are listed in the provided data, Turn’s public communications reference its status as a Nasdaq-listed company and describe a direct listing structure used to enter the public markets.
For a company like Turn Therapeutics, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on clinical programs such as GX-03 for moderate to severe atopic dermatitis, late-stage efforts in onychomycosis, and vaccine initiatives based on its PermaFusion delivery platform. These reports often include discussions of research and development spending, risk factors related to clinical trials and regulatory pathways, and descriptions of commercial agreements, such as the global supply, development, and license agreement with Medline.
Other important SEC documents for a Nasdaq-listed biotechnology company can include current reports on Form 8-K, which may disclose material events like new strategic partnerships, changes to the Board of Directors, or significant financing arrangements. Filings related to equity financing structures, such as the GEM Global Yield agreement and share purchase agreements referenced in company updates, are also commonly detailed in SEC submissions.
On Stock Titan, Turn Therapeutics filings are supplemented with AI-powered summaries designed to explain key sections of lengthy documents in clear language. These tools can help users quickly understand complex topics such as clinical development disclosures, collaboration terms, and capital strategy without reading every page. As new TTRX filings are made available through EDGAR, this page can serve as a starting point for reviewing the company’s regulatory and financial reporting history.
Turn Therapeutics director Martin William Dewhurst received a grant of stock options covering 71,666 shares of Common Stock at an exercise price of $5.75 per share. The options vest in twelve equal monthly installments beginning on June 30, 2026 and expire on June 4, 2036.
Following this award, he holds 71,666 stock options directly, all tied to continued employment and the terms of the 2025 Omnibus Incentive Plan.
Turn Therapeutics director Andrew Gengos received a grant of stock options covering 95,000 shares of common stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036. They vest in twelve equal monthly installments starting on June 30, 2026, contingent on his continued employment under the company’s 2025 Omnibus Incentive Plan. This is a compensation-related award, not an open-market share purchase or sale.
Turn Therapeutics Inc. director Arthur F. Golden received a grant of stock options for 89,584 shares of common stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036. They vest in twelve equal monthly installments beginning on June 30, 2026, contingent on continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. Following this award, Golden holds 89,584 option-based rights directly.
Turn Therapeutics Inc. director Kester Kent Edward received a grant of stock options covering 83,334 shares of Common Stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036.
The option award vests in twelve equal monthly installments on the last day of each month, beginning June 30, 2026, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. Following this grant, the reporting person holds 83,334 stock options directly.
Turn Therapeutics Inc. furnished an updated investor presentation outlining its dermatology pipeline, lead asset GX-03 and financial position. The company describes GX-03 as a non-systemic immunomodulation therapy targeting IL-36 and IL-31 for moderate to severe atopic dermatitis, supported by interim Phase 2 data showing meaningful reductions in EASI scores versus vehicle and a favorable safety profile.
The presentation also highlights Phase 3–ready data for onychomycosis, where GX-03 showed nail penetration and fungal burden reduction, and broader opportunities using its PermaFusion delivery platform. Financially, Turn reports $11M in cash as of March 31, 2026, total funding of $29M since 2015, expected Phase 3 R&D spend of $55–60M across two indications, and cash runway into Q1 2027.
Turn Therapeutics Inc. director and Chief Executive Officer Bradley E. Burnam reported a series of bona fide gifts of the company’s common stock on May 28, 2026. The filing shows four gift transactions totaling 1,200,000 shares, each recorded at a price of $0.0000 per share, meaning no cash changed hands.
Part of the stock is held and transferred through BEB Holdings, LLC, where Burnam is the sole member with sole voting and dispositive power. Other portions were gifted to two 2026 revocable trusts established for his daughter and son. The filing states Burnam disclaims beneficial ownership of the shares held by these trusts for Section 16 and other purposes.
Turn Therapeutics reported interim results from the first 50 subjects in its randomized, double-blind, vehicle-controlled Phase 2 trial of topical GX-03 for moderate-to-severe atopic dermatitis. In this interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in eczema severity at 4 weeks (EASI-50), compared with 65.2% for vehicle.
Deeper response thresholds also favored GX-03, with Week 4 EASI-90 responses of 44.4% versus 30.4% for vehicle, rising by Week 8 to 51.9% versus 34.8%. No treatment-related serious adverse events, tolerability issues, or discontinuations were observed during the interim period, supporting a favorable safety and tolerability profile.
The company is using these findings to refine enrollment criteria, endpoint hierarchy, and overall trial optimization while enrollment continues, and plans FDA interactions to discuss regulatory strategy for GX-03. Turn Therapeutics expects to present more detailed data at the Jefferies Global Healthcare conference on June 4, 2026.
Turn Therapeutics filed a current report to share that a peer-reviewed article on its lead program, GX-03, has been published in the Journal of Dermatological Treatment. The study evaluated GX-03 in an IL-36–associated inflammatory model of Staphylococcus aureus–induced murine dermatitis and observed a clear clinical effect after seven days of twice-daily treatment.
The publication supports Turn’s strategy of targeting inflammation locally at the skin, focusing on cytokines such as IL-36. GX-03 is described as a first-in-class, non-systemic topical cytokine‑modulating therapy in development for moderate-to-severe atopic dermatitis and is currently in a Phase 2 randomized controlled trial, with topline results expected in mid-2026.
Turn Therapeutics Inc. filed a current report to share that its CEO, Bradley Burnam, will present at the Jefferies Global Healthcare Conference in New York City on June 4, 2026, from 9:55 AM to 10:25 AM EDT. A live webcast and a replay for about six months will be available on the company’s investor relations website. The company highlights its lead investigational therapy GX-03, a topical inhibitor for moderate-to-severe atopic dermatitis targeting IL-36 and IL-31, which is in a Phase 2 randomized controlled trial with topline results expected in mid-2026.
Turn Therapeutics Inc. announced that it has appointed Stephen M. Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration, as its executive clinical and regulatory lead. He will oversee clinical and regulatory strategy for GX-03, the company’s investigational topical therapy for moderate-to-severe atopic dermatitis, which is currently in a Phase 2 randomized controlled trial with topline results expected in mid-2026.
GX-03 is described as a first-in-class, non-systemic, topical cytokine‑modulating therapy aimed at key inflammatory pathways in eczema and other inflammatory skin diseases. Turn Therapeutics positions itself as a biotechnology company focused on targeted, localized therapies for inflammatory diseases with high unmet medical need.